The delivery of triamterene by cucurbit[7]uril: Synthesis, structures and pharmacokinetics study

Molecular Pharmaceutics

Volumn 10, Issue 12, 2013, Pages 4698-4705

  Ma, Wen Juan ^a   Chen, Jia Mei ^a   Jiang, Long ^a   Yao, Jia ^a   Lu, Tong Bu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

crystal structure; cucurbit 7 uril; pharmacokinetics; solubility; triamterene

Indexed keywords

CUCURBIT[7]URIL; EXCIPIENT; TRIAMTERENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EXCRETION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MACROCYCLIC COMPOUNDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TRIAMTERENE; WATER; X-RAY DIFFRACTION;

EID: 84889245200     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400529m     Document Type: Article

References (60)

1. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 (Pubitemid 27046991)
2. Lipinski, C. A. Poor Aqueous Solubility-an Industry Wide Problem in ADME Screening Am. Pharm. Rev. 2002, 5, 82-85
3. Shan, N.; Zaworotko, M. J. The role of cocrystals in pharmaceutical science Drug Discovery Today 2008, 13, 440-446
4. Weyna, D. R.; Cheney, M. L.; Shan, N.; Hanna, M.; Zaworotko, M. J.; Sava, V.; Song, S.; Sanchez-Ramos, J. R. Improving Solubility and Pharmacokinetics of Meloxicam via Multiple-Component Crystal Formation Mol. Pharmaceutics 2012, 9, 2094-2102
5. Serajuddin, A. T. M. Salt formation to improve drug solubility Adv. Drug Delivery Rev. 2007, 59, 603-616 (Pubitemid 47285406)
6. Stella, V. J.; Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility Adv. Drug Delivery Rev. 2007, 59, 677-694 (Pubitemid 47285410)
7. Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 2000, 50, 47-60 (Pubitemid 30326688)
8. Morrison, P. W. J.; Connon, C. J.; Khutoryanskiy, V. V. Cyclodextrin-Mediated Enhancement of Riboflavin Solubility and Corneal Permeability Mol. Pharmaceutics 2013, 10, 756-762
9. Walker, S.; Oun, R.; McInnes, F. J.; Wheate, N. J. The Potential of Cucurbit[n]urils in Drug Delivery Isr. J. Chemistry 2011, 51, 616-624
10. Baba, W. I.; Tudhope, G. R.; Wilson, G. M.; Triamterene, A. New Diuretic Drug: I. Studies In Normal Men And In Adrenalectomized Rats Br. Med. J. 1962, 2, 756-760
11. Hansen, K. B.; Bender, A. D. Changes in serum potassium levels occurring in patients treated with triamterene and a triamterene-hydrochlorothiazide combination Clin. Pharmacol. Ther. 1967, 8, 392-399
12. Dittert, L. W.; Higuchi, T.; Reese, D. R. Phase solubility technique in studying the formation of complex salts of triamterene J. Pharm. Sci. 1964, 53, 1325-1328
13. Pruitt, A. W.; Winkel, J. S.; Dayton, P. G. Variations in the fate of triameterene Clin. Pharmacol. Ther. 1977, 21, 610-619
14. Arias, M. J.; Moyano, J. R.; Ginés, J. M. Investigation of the triamterene-β-cyclodextrin system prepared by co-grinding Int. J. Pharm. 1997, 153, 181-189
15. Mukne, A.; Nagarsenker, M. S. Triamterene-β-cyclodextrin systems: Preparation, characterization and in vivo evaluation AAPS PharmSciTech 2004, 5, 142-150
16. Arias, M. J.; Gines, J. M.; Moyano, J. R.; Rabasco, A. M. The application of solid dispersion technique with D-mannitol to the improvement in oral absorption of triamterene J. Drug Targeting 1994, 2, 45-51 (Pubitemid 24106959)
17. Arias, M. J.; Ginés, J. M.; Moyano, J. R.; Pérez-Martinez, J. I.; Rabasco, A. M. Influence of the preparation method of solid dispersions on their dissolution rate: Study of triamterene-d-mannitol system Int. J. Pharm. 1995, 123, 25-31
18. Frank, D.; Gray, J.; Weaver, R. Cyclodextrin nephrosis in the rat Am. J. Pathol. 1976, 83, 367-382
19. Serajuddin, A. T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 1999, 88, 1058-1066
20. Liu, S.; Zavalij, P. Y.; Lam, Y.-F.; Isaacs, L. Refolding Foldamers: Triazene-Arylene Oligomers That Change Shape with Chemical Stimuli J. Am. Chem. Soc. 2007, 129, 11232-11241 (Pubitemid 47435726)
21. Lim, S.; Kim, H.; Selvapalam, N.; Kim, K.-J.; Cho, S. J.; Seo, G.; Kim, K. Cucurbit[6]uril: Organic Molecular Porous Material with Permanent Porosity, Exceptional Stability, and Acetylene Sorption Properties Angew. Chem., Int. Ed. 2008, 47, 3352-3355
22. Ghosh, S.; Isaacs, L. Biological Catalysis Regulated by Cucurbit[7]uril Molecular Containers J. Am. Chem. Soc. 2010, 132, 4445-4454
23. Lee, D.-W.; Park, K. M.; Banerjee, M.; Ha, S. H.; Lee, T.; Suh, K.; Paul, S.; Jung, H.; Kim, J.; Selvapalam, N.; Ryu, S. H.; Kim, K. Supramolecular fishing for plasma membrane proteins using an ultrastable synthetic host-guest binding pair Nat. Chem. 2011, 3, 154-159
24. Park, K. M.; Suh, K.; Jung, H.; Lee, D.-W.; Ahn, Y.; Kim, J.; Baek, K.; Kim, K. Cucurbituril-based nanoparticles: a new efficient vehicle for targeted intracellular delivery of hydrophobic drugs Chem. Commun. 2009, 7, 71-73
25. Kim, S. K.; Park, K. M.; Singha, K.; Kim, J.; Ahn, Y.; Kim, K.; Kim, W. J. Galactosylated cucurbituril-inclusion polyplex for hepatocyte-targeted gene delivery Chem. Commun. 2010, 46, 692-694
26. Freeman, W. A.; Mock, W. L.; Shih, N. Y. Cucurbituril J. Am. Chem. Soc. 1981, 103, 7367-7368
27. Kim, J.; Jung, I.-S.; Kim, S.-Y.; Lee, E.; Kang, J.-K.; Sakamoto, S.; Yamaguchi, K.; Kim, K. New Cucurbituril Homologues: Syntheses, Isolation, Characterization, and X-ray Crystal Structures of Cucurbit[n]uril (n = 5, 7, and 8) J. Am. Chem. Soc. 2000, 122, 540-541 (Pubitemid 30075495)
28. Day, A. I.; Blanch, R. J.; Arnold, A. P.; Lorenzo, S.; Lewis, G. R.; Dance, I. A Cucurbituril-Based Gyroscane: A New Supramolecular Form Angew. Chem., Int. Ed. 2002, 41, 275-277 (Pubitemid 34118068)
29. Liu, S.; Zavalij, P. Y.; Isaacs, L. Cucurbit[10]uril J. Am. Chem. Soc. 2005, 127, 16798-16799 (Pubitemid 41772835)
30. Cheng, X.-J.; Liang, L.-L.; Chen, K.; Ji, N.-N.; Xiao, X.; Zhang, J.-X.; Zhang, Y.-Q.; Xue, S.-F.; Zhu, Q.-J.; Ni, X.-L.; Tao, Z. Twisted Cucurbit[14]uril Angew. Chem., Int. Ed. 2013, 52, 7252-7255
31. Lagona, J.; Mukhopadhyay, P.; Chakrabarti, S.; Isaacs, L. The Cucurbit[n]uril Family Angew. Chem., Int. Ed. 2005, 44, 4844-4870 (Pubitemid 41138666)
32. Lee, J. W.; Samal, S.; Selvapalam, N.; Kim, H.-J.; Kim, K. Cucurbituril Homologues and Derivatives: New Opportunities in Supramolecular Chemistry Acc. Chem. Res. 2003, 36, 621-630
33. Wang, R.; Macartney, D. H. Cucurbit[7]uril host-guest complexes of the histamine H2-receptor antagonist ranitidine Org. Biomol. Chem. 2008, 6, 1955-1960 (Pubitemid 351693241)
34. Wyman, I. W.; Macartney, D. H. Host-guest complexations of local anaesthetics by cucurbit[7]uril in aqueous solution Org. Biomol. Chem. 2010, 8, 247-252
35. Isaacs, L. Cucurbit[n]urils: from mechanism to structure and function Chem. Commun. 2009, 619-629
36. Uzunova, V. D.; Cullinane, C.; Brix, K.; Nau, W. M.; Day, A. I. Toxicity of cucurbit[7]uril and cucurbit[8]uril: an exploratory in vitro and in vivo study Org. Biomol. Chem. 2010, 8, 2037-2042
37. Hettiarachchi, G.; Nguyen, D.; Wu, J.; Lucas, D.; Ma, D.; Isaacs, L.; Briken, V. Toxicology and drug delivery by cucurbit[n]uril type molecular containers PLoS One 2010, 5, e10514
38. Montes-Navajas, P.; Gonzalez-Bejar, M.; Scaiano, J. C.; Garcia, H. Cucurbituril complexes cross the cell membrane Photochem. Photobiol. Sci. 2009, 8, 1743-1747
39. Walker, S.; Kaur, R.; McInnes, F. J.; Wheate, N. J. Synthesis, Processing and Solid State Excipient Interactions of Cucurbit[6]uril and Its Formulation into Tablets for Oral Drug Delivery Mol. Pharmaceutics 2010, 7, 2166-2172
40. Ghosh, I.; Nau, W. M. The strategic use of supramolecular pKa shifts to enhance the bioavailability of drugs Adv. Drug Delivery Rev. 2012, 64, 764-783
41. Koner, A. L.; Ghosh, I.; Saleh, N. i.; Nau, W. M. Supramolecular encapsulation of benzimidazole-derived drugs by cucurbit[7]uril Can. J. Chem. 2011, 89, 139-147
42. Zhao, Y.; Buck, D. P.; Morris, D. L.; Pourgholami, M. H.; Day, A. I.; Collins, J. G. Solubilisation and cytotoxicity of albendazole encapsulated in cucurbit[n]uril Org. Biomol. Chem. 2008, 6, 4509-4515
43. Zhao, Y.; Pourgholami, M. H.; Morris, D. L.; Collins, J. G.; Day, A. I. Enhanced cytotoxicity of benzimidazole carbamate derivatives and solubilisation by encapsulation in cucurbit[n]uril Org. Biomol. Chem. 2010, 8, 3328-3337
44. Kennedy, A. R.; Florence, A. J.; McInnes, F. J.; Wheate, N. J. A chemical preformulation study of a host-guest complex of cucurbit[7]uril and a multinuclear platinum agent for enhanced anticancer drug delivery Dalton Trans. 2009, 7695-7700
45. McInnes, F. J.; Anthony, N. G.; Kennedy, A. R.; Wheate, N. J. Solid state stabilisation of the orally delivered drugs atenolol, glibenclamide, memantine and paracetamol through their complexation with cucurbit[7]uril Org. Biomol. Chem. 2010, 8, 765-773
46. Jackson, K.; Young, D.; Pant, S. Drug-excipient interactions and their affect on absorption Pharm. Sci. Technol. Today 2000, 3, 336-345
47. Li, C.; Wang, J.-X.; Le, Y.; Chen, J.-F. Studies of Bicalutamide- Excipients Interaction by Combination of Molecular Docking and Molecular Dynamics Simulation Mol. Pharmaceutics 2013, 10, 2362-2369
48. Khomane, K. S.; More, P. K.; Raghavendra, G.; Bansal, A. K. Molecular understanding of the compaction behavior of indomethacin polymorphs Mol. Pharmaceutics 2013, 10, 631-639
49. Chen, J.-M.; Wang, Z.-Z.; Wu, C.-B.; Li, S.; Lu, T.-B. Crystal engineering approach to improve the solubility of mebendazole CrystEngComm. 2012, 14, 6221-6229
50. Marquez, C.; Huang, F.; Nau, W. M. Cucurbiturils molecular nanocapsules for time-resolved fluorescence-based assays IEEE Trans. Nanobiosci. 2004, 3, 39-45
51. Version, C. 1.171. 35.19, 2011. Agilent Technologies Inc., Santa Clara, CA, USA.
52. Sheldrick, G. M. A short history of SHELX Acta Crystallogr., A 2008, 64, 112-122
53. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A.; Puschmann, H. OLEX2: a complete structure solution, refinement and analysis program J. Appl. Crystallogr. 2009, 42, 339-341
54. Spek, A. Single-crystal structure validation with the program PLATON J. Appl. Crystallogr. 2003, 36, 7-13
55. Sygula, A.; Fronczek, F. R.; Sygula, R.; Rabideau, P. W.; Olmstead, M. M. A Double Concave Hydrocarbon Buckycatcher J. Am. Chem. Soc. 2007, 129, 3842-3843 (Pubitemid 46595503)
56. Hamidi, M.; Shahbazi, M. A.; Azimi, K. Bioequivalence evaluation of a triamterene-hydrochlorothiazide generic product: a new bioequivalence index for fixed-dose combinations Regul. Toxicol. Pharmacol. 2011, 59, 149-156
57. Ostwald, W. Studien uber die Bildung und Umwandlung fester Korper Z. Phys. Chem. 1897, 22, 289-330
58. Tang, H.; Fuentealba, D.; Ko, Y. H.; Selvapalam, N.; Kim, K.; Bohne, C. Guest Binding Dynamics with Cucurbit[7]uril in the Presence of Cations J. Am. Chem. Soc. 2011, 133, 20623-20633
59. Gundert-Remy, U.; Kenne, D.; Weber, E.; Geißler, H. E.; Grebian, B.; Mutschler, E. Plasma and urinary levels of triamterene and certain metabolites after oral administration to man Eur. J. Clin. Pharmacol. 1979, 16, 39-44 (Pubitemid 9235744)
60. Hasegawa, J.; Lin, E.; Williams, R.; Sörgel, F.; Benet, L. Pharmacokinetics of triamterene and its metabolite in man J. Pharmacokinet. Biopharm. 1982, 10, 507-523 (Pubitemid 13185255)